fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Amantadine HCL

Form:

5 of 5 products shown

3 general benefit · 2 not a benefit

Odan-Amantadine Syrup · DIN 02538601 · 10 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Odan-Amantadine Syrup · DIN 02538601 Manufacturer: Odan Laboratories Ltd.; listing date 2023-10-31 Health Canada: Marketed since 2023-07-20 · brand ODAN-AMANTADINE SYRUP · ATC N04BB01 AMANTADINE, N04BB01 AMANTADINE · form Syrup · route Oral · ingredients AMANTADINE HYDROCHLORIDE 10 MG/ML · company Odan laboratoriesltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Odan-Amantadine Syrup: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0988). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02538601)

Source record
DIN 02538601: Odan-Amantadine Syrup Raw flags: sec3=Y Item: 920000032; group id 895; item number 2150; lccId None; manufacturer id ODN Source form: O/L; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0988; ministry $0.0988 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02538601 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102731
Interchangeable products
PDP-Amantadine Hydrochloride Syrup · DIN 02022826 · $0.0988 Symmetrel · DIN 01913999 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538601
Shortage record checked October 6, 2026

PDP-Amantadine Hydrochloride Syrup · DIN 02022826 · 10 mg/mL · oral liquid

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PDP-Amantadine Hydrochloride Syrup · DIN 02022826 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1997-08-28 Health Canada: Marketed since 2018-01-05 · brand PDP-AMANTADINE HYDROCHLORIDE SYRUP · ATC N04BB01 AMANTADINE · form Syrup · route Oral · ingredients AMANTADINE HYDROCHLORIDE 50 MG/5ML · company Pendopharm division of pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PDP-Amantadine Hydrochloride Syrup: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0988). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02022826)

Source record
DIN 02022826: PDP-Amantadine Hydrochloride Syrup Raw flags: sec3=Y Item: 920000032; group id 895; item number 2150; lccId None; manufacturer id PEN Source form: O/L; strength: 10mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0988; ministry $0.0988 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02022826 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14393
Interchangeable products
Odan-Amantadine Syrup · DIN 02538601 · $0.0988 Symmetrel · DIN 01913999 · not recorded
Shortage status: resolved shortage (ended January 7, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02022826
Shortage record checked October 6, 2026

PDP-Amantadine Hydrochloride Capsules · DIN 01990403 · 100 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PDP-Amantadine Hydrochloride Capsules · DIN 01990403 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 2017-03-15 · brand PDP-AMANTADINE HYDROCHLORIDE CAPSULES · ATC N04BB01 AMANTADINE, N04BB01 AMANTADINE · form Capsule · route Oral · ingredients AMANTADINE HYDROCHLORIDE 100 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PDP-Amantadine Hydrochloride Capsules: Formulary list price $0.57 per unit (the source does not state the unit; exact figure $0.5662). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01990403)

Source record
DIN 01990403: PDP-Amantadine Hydrochloride Capsules Raw flags: sec3=Y Item: 920000021; group id 895; item number 2149; lccId None; manufacturer id PEN Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.5662; ministry $0.5662 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01990403 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13464
Interchangeable products
Symmetrel · DIN 01914006 · not recorded
Shortage status: resolved shortage (ended February 9, 2018); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01990403
Shortage record checked October 6, 2026

Symmetrel · DIN 01913999 · 10 mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.Discontinued November 3, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Symmetrel · DIN 01913999 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-11-03 · brand SYMMETREL SYRUP 10MG/ML · ATC N04BB01 AMANTADINE, N04BB01 AMANTADINE · form Syrup · route Oral · ingredients AMANTADINE HYDROCHLORIDE 10 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Symmetrel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01913999)

Source record
DIN 01913999: Symmetrel Raw flags: notABenefit=Y, sec3=Y Item: 920000032; group id 895; item number 2150; lccId None; manufacturer id BQU Source form: O/L; strength: 10mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01913999 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15546
Interchangeable products
Odan-Amantadine Syrup · DIN 02538601 · $0.0988 PDP-Amantadine Hydrochloride Syrup · DIN 02022826 · $0.0988
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913999
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 3, 2008 — choose a marketed DIN from the same-category list.

Symmetrel · DIN 01914006 · 100 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.Discontinued September 4, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Symmetrel · DIN 01914006 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-09-04 · brand SYMMETREL CAPSULES 100MG · ATC N04BB01 AMANTADINE, N04BB01 AMANTADINE · form Capsule · route Oral · ingredients AMANTADINE HYDROCHLORIDE 100 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Symmetrel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01914006)

Source record
DIN 01914006: Symmetrel Raw flags: notABenefit=Y, sec3=Y Item: 920000021; group id 895; item number 2149; lccId None; manufacturer id BQU Source form: Cap; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01914006 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13581
Interchangeable products
PDP-Amantadine Hydrochloride Capsules · DIN 01990403 · $0.5662
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01914006
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 4, 2008 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N04B): coverage varies; not interchangeable

  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, limited Use, not a benefit
  • Ropinirole (ReQuip): general benefit, not a benefit
  • Selegiline (Eldepryl): general benefit, not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Antiparkinsonian Treatment pdp-AMANTADINE HYDROCHLORIDE is useful in the treatment of Parkinson's Syndrome and in the short-term management of drug-induced extrapyramidal symptoms. Antiviral Prevention and Treatment  The prevention or chemoprophylaxis of respiratory tract infections caused by Influenza A virus strains, especially in high-risk patients (including those with cardiopulmonary disease, neuromuscular disorders, the elderly, immunocompromised), close household or hospital ward contact of index cases, and those in critical public service positions (e.g. police, firefighters, and medical personnel). In the prophylaxis of influenza early vaccination is the method of choice. When early vaccination is not feasible, or when the vaccine is contraindicated or not available, amantadine hydrochloride may be used for chemoprophylaxis against influenza A virus illness. It is effective against all strains of Influenza A virus which have been tested to date. Because amantadine hydrochloride does not appear to suppress antibody response, it may be given as chemoprophylaxis concurrently with inactivated Influenza A virus vaccine until prot… https://pdf.hres.ca/dpd_pm/00066300.PDF PM date: Jun 13, 2022 Source product: PDP-AMANTADINE HYDROCHLORIDE CAPSULES; DIN 01990403; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Symmetrel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026